



UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | 09/399, 083 | 09/17/99 | CALDERWOOD | D | BBC-043PA2

HM22/0424

RICHARD W WAGNER
HAMILTON BROOK SMITH & REYNOLDS
TWO MILITIA DRIVE
LEXINGTON MA 02421-4799

EXAMINER	
RAO,D	
ART UNIT	PAPER NUMBER
1624	1. 6'

DATE MAILED:

04/24/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Office Action Summary

Application No. **09/399,083**

Applicant(s)

Calderwood et al.

Examiner

D pak Rao

Art Unit **1624**



The MAILING DATE of this communication appear	rs on th cov r sheet with the corresp ndenc address
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS S THE MAILING DATE OF THIS COMMUNICATION.	
communication.	n. eply within the statutory minimum of thirty (30) days will od will apply and will expire SIX (6) MONTHS from the mailing date of this ute, cause the application to become ABANDONED (35 U.S.C. § 133).
Status	
1) 🛛 Responsive to communication(s) filed on <u>Feb 13</u> ,	2001
2a) ☐ This action is FINAL . 2b) ☒ This action	ction is non-final.
3) Since this application is in condition for allowance closed in accordance with the practice under Exp	
Disposition of Claims	
4) 🗓 Claim(s) <u>1-8 and 10-48</u>	● are pending in the applica
4a) Of the above, claim(s)	is/are withdrawn from considers
5)	is/are allowed.
	is/are rejected.
	is/are objected to.
8) 🗓 Claims <u>1-8 and 10-48</u>	are subject to restriction and/or election requirem
Application Papers	
9) The specification is objected to by the Examiner.	
10) The drawing(s) filed on is	/are objected to by the Examiner.
11) The proposed drawing correction filed on	
12) The oath or declaration is objected to by the Exami	
Priority under 35 U.S.C. § 119	
13) Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d).
a) ☐ All b) ☐ Some* c) ☐None of:	1
1. Certified copies of the priority documents have	e been received
2. Certified copies of the priority documents have	e been received in Application No.
 Copies of the certified copies of the priority do application from the International Burea *See the attached detailed Office action for a list of the 	
14) Acknowledgement is made of a claim for domestic	
Attachment(s)	
15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
16) Notice of Praftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:

Art Unit: 1624

DETAILED ACTION

Continued Prosecution Application

The request filed on February 13, 2001 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/399,083 is acceptable and a CPA has been established. An action on the CPA follows.

Claims 1-8 and 10-48 are pending in this application.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-8, 10-11 and 46-48, drawn to compounds, classified in class 544, subclass various.
- II. Claims 12-38 and 40-45, drawn to a method of use (related to protein kinases) of the compounds, classified in class 514, subclass various.
- III. Claim 39, drawn to another method of use of the compounds (decreasing fertility in a patient), classified in class 514, subclass various.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II-III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product

Art Unit: 1624

as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products as claimed in Invention I can be used in materially different processes of inventions II and III. Also, the products of invention I are also used in a different process as shown by reference of record, US 5,834,469, wherein the products are disclosed to have endothelin receptor activity and are useful in corresponding therapeutic methods. It is also known to inhibit protein kinases by methods employing products other than those of invention I.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: as shown in claims 1-8, 10-11 and 46-48.

Applicant is required under 35 U.S.C. 121 to **elect a single disclosed species** for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Art Unit: 1624

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Rao whose telephone number is (703) 305-1879. The fax phone number for this Group is (703) 308-4556. Any inquiry of a general nature or relating to the status

Art Unit: 1624

of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Deepak Rao April 22, 2001

Mukund J. Shah
Supervisory Patent Examiner
Art Unit 1624